apomorphine hydrochloride — Regulatory decision
Mid 2027
In addition, the Company submitted a supplemental New Drug Application (sNDA) to the FDA for a second supplier for ONAPGO and continues to expect potential FDA approval of the second supplier by mid-year 2027.Source filing